Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)
Avalo Therapeutics (AVTX) reported Cost of Revenue of $714,000 for Q3 2024, up 189.1% from $247,000 a year earlier and up 108.2% from the prior quarter.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024) Analysis & Trends
For FY2023, Avalo Therapeutics posted Cost of Revenue of $1.28 million, down 62.6% from FY2022.
- Cost of Revenue has a five-year compound annual growth rate of -17.0% (FY2018 to FY2023).
- By year, Cost of Revenue came in at $3.43 million in FY2022 (+130.3%), $1.49 million in FY2021 (+397.0%), $300,000 in FY2020 (-47.0%) and $566,523 in FY2019 (-82.6%).
- The Q3 2024 figure ranks as the highest quarterly Cost of Revenue since Q2 2022.
- Year over year, Cost of Revenue gained in two of the last seven quarters, with an average decline of 4.7%.
- The high point for year-over-year Cost of Revenue in five years was Q1 2022 (growth of 835.1%); the low point was Q2 2020 (a decline of 94.8%).
- Per Business Quant data, the three quarters before Q3 2024 came in at $343,000 (Q2 2024), $80,000 (Q1 2024) and -$221,000 (Q4 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 3.27 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 8.10 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 4.29 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 4.40 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 3.71 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 2.52 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 2.81 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 1.58 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 4.09 Bn |
| 10 | Avalo Therapeutics | 302.16 Mn | -390.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 714,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | -221,000.00 |
| Sep 30, 2023 | 247,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 720,000.00 |
| Dec 31, 2021 | 424,000.00 |
| Sep 30, 2021 | 908,000.00 |
| Jun 30, 2021 | 83,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Dec 31, 2020 | 79,000.00 |
| Sep 30, 2020 | 77,000.00 |
| Jun 30, 2020 | 78,000.00 |
| Mar 31, 2020 | 66,000.00 |
| Dec 31, 2019 | -2.67 Mn |
API Access
Avalo Therapeutics Cost of Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=AVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cost-of-revenue", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();